



Providing Choice & Value

Generic CT and MRI Contrast Agents



CONTACT REP

AJNR

This information is current as of July 19, 2025.

Endarterectomy, Stenting, or Medical Treatment for Symptomatic Carotid Near-Occlusion: Results from CAOS, a Multicenter Registry Study
























A. Garcia-Pastor, A. Gil-Núñez, J.M. Ramirez-Moreno, N. González-Nafría, J. Tejada, F. Moniche, J.C. Portilla-Cuenca, P. Martínez-Sánchez, B. Fuentes, M.A. Gamero-García, M.A. de Leciñana, J. Masjuan, D.C. Verge, Y. Aladro, V. Parkhutik, A. Lago, A.M. de Arce-Borda, M. Usero-Ruiz, R. Delgado-Mederos, A. Pampliega, Á. Ximenez-Carrillo, M. Bártulos-Iglesias, E. Castro-Reyes and on behalf of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group

AJNR Am J Neuroradiol 2022, 43 (9) 1304-1310

doi: <https://doi.org/10.3174/ajnr.A7617>

<http://www.ajnr.org/content/43/9/1304>

Endarterectomy, Stenting, or Medical Treatment for Symptomatic Carotid Near-Occlusion: Results from CAOS, a Multicenter Registry Study

 A. Garcia-Pastor,  A. Gil-Núñez,  J.M. Ramirez-Moreno,  N. González-Nafria,  J. Tejada,  F. Moniche,  J.C. Portilla-Cuenca,  P. Martínez-Sánchez,  B. Fuentes,  M.A. Gamero-García,  M.A. de Leciñana,  J. Masjuan,  D.C. Verge,  Y. Aladro,  V. Parkhutik,  A. Lago,  A.M. de Arce-Borda,  M. Usero-Ruiz,  R. Delgado-Mederos,  A. Pampliega,  Á. Ximenez-Carrillo,  M. Bártulos-Iglesias, and  E. Castro-Reyes, on behalf of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group



ABSTRACT

BACKGROUND AND PURPOSE: The treatment of symptomatic carotid near-occlusion is controversial. Our aim was to analyze the results of carotid endarterectomy and carotid artery stent placement in patients with symptomatic carotid near-occlusion and to identify factors related to technical failure, periprocedural complications, and restenosis.

MATERIALS AND METHODS: We conducted a multicenter, prospective nonrandomized study. Patients with angiography-confirmed carotid near-occlusion were included. We assessed the revascularization rate and periprocedural stroke or death. Twenty-four-month clinical and carotid imaging follow-up was performed, and rates of carotid restenosis or occlusion, ipsilateral stroke, and mortality were analyzed. Carotid artery stent placement, carotid endarterectomy, and medical treatment were compared.

RESULTS: One hundred forty-one patients were included. Forty-four carotid artery stent placement and 23 carotid endarterectomy procedures were performed within 6 months after the event. Complete revascularization was achieved in 83.6%, 81.8% in the carotid artery stent placement group and 87% with carotid endarterectomy ($P = .360$). Periprocedural stroke or death occurred in 6% (carotid artery stent placement = 2.3%; carotid endarterectomy = 13%; $P = .077$) and was not related to revascularization failure. The carotid restenosis or occlusion rate was 8.3% (5% restenosis, 3.3% occlusion); with carotid artery stent placement it was 10.5%; and with carotid endarterectomy it was 4.5% ($P = .419$). The 24-month cumulative rate of ipsilateral stroke was 4.8% in the carotid artery stent placement group, 17.4% for carotid endarterectomy, and 13.1% for medical treatment ($P = .223$). Mortality was 12%, 4.5%, and 5.6%, respectively ($P = .422$). Revascularization failure and restenosis occurred more frequently in patients with full collapse compared with patients without full collapse (33.3% versus 5.6%, $P = .009$; 21.4% versus 2.9%, $P = .032$, respectively).

CONCLUSIONS: Carotid artery stent placement and carotid endarterectomy are associated with high rates of failure and periprocedural stroke. Carotid near-occlusion with full collapse appears to be associated with an increased risk of technical failure and restenosis. Carotid near-occlusion revascularization does not seem to reduce the risk of stroke at follow-up compared with medical treatment.

ABBREVIATIONS: CAS = carotid artery stent placement; CEA = carotid endarterectomy; CHS = cerebral hyperperfusion syndrome; CNO = carotid near-occlusion; IQR = interquartile range

The treatment of symptomatic carotid near-occlusion (CNO) is controversial. Post hoc analyses of the NASCET and the

European Carotid Surgery Trial (ECST) conducted in the 1990s revealed that the risk of recurrent stroke could be lower in

Received March 15, 2022; accepted after revision June 17.

From the Department of Neurology (A.G.-P., A.G.-N., E.C.-R.), Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Neurology (J.M.R.-M.), Hospital Universitario Infanta Cristina, Badajoz, Spain; Department of Neurology (N.G.-N., J.T.), Complejo Asistencial Universitario de León, Neurology, León, Spain; Department of Neurology (F.M.), Hospital Universitario Virgen del Rocío, Sevilla, Spain; Department of Neurology (J.C.P.-C.), Hospital San Pedro Alcántara, Cáceres, Spain; Department of Neurology (P.M.-S., B.F.), Hospital Universitario La Paz, Madrid, Spain; Department of Neurology (M.A.G.-G.), Hospital Universitario Virgen Macarena, Sevilla, Spain; Department of Neurology (M.A.d.L., J.M.), Hospital Universitario Ramón y Cajal, Madrid, Spain; Department of Neurology (D.C.V.), Corporació Sanitaria Parc Taulí, Sabadell, Spain; Department of Neurology (Y.A.), Hospital Universitario de Getafe, Getafe, Spain; Department of Neurology (V.P., A.L.),

Hospital Universitari La Fe, Valencia, Spain; Department of Neurology (A.M.d.A.-B.), Hospital Universitario de Donostia, Donostia, Spain; Department of Neurology (M.U.-R.), Hospital Universitario de Valladolid, Valladolid, Spain; Department of Neurology (R.D.-M.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (A.P.), Hospital General Universitario de Alicante, Alicante, Spain; Department of Neurology (Á.X.-C.), Hospital Universitario de La Princesa, Madrid, Spain; and Department of Neurology (M.B.-I.), Hospital Universitario de Burgos, Burgos, Spain. Please address correspondence to Andrés García-Pastor, MD, Stroke Center, Vascular Neurology Section, Hospital General Universitario Gregorio Marañón, Madrid, Spain, C/Dr Esquerdo 46, 28007 Madrid, Spain; e-mail: angarpas@yahoo.es; @angarpas1

<http://dx.doi.org/10.3174/ajnr.A7617>

patients with CNO than in patients with conventional severe carotid stenosis and that patients with CNO might not benefit from revascularization.¹⁻³ On the basis of this evidence, the latest guidelines of the European Society for Vascular Surgery do not recommend revascularization in patients with CNO.⁴ However, recent studies have reported a higher recurrence rate in patients with CNO, especially when associated with full collapse,^{5,6} and several meta-analyses have shown the nonsuperiority of best medical treatment over revascularization therapies.⁷⁻⁹

Many case series have shown that both carotid endarterectomy (CEA) and carotid artery stent placement (CAS) are effective and safe in patients with CNO.¹⁰⁻¹⁵ However, most of these studies are retrospective single-center series that do not even compare the 2 techniques. To date, only 2 retrospective studies have directly compared CEA and CAS in patients with CNO with similar rates of periprocedural complications and long-term recurrences.^{16,17} Additionally, recent pooled analyses did not show relevant differences between CEA and CAS in CNO in both periprocedural and long-term follow-up.^{8,9} Unfortunately, we do not have better quality evidence because the latest clinical trials comparing CAS and CEA in the treatment of symptomatic carotid stenosis did not include patients with CNO.^{18,19}

The objectives of this study were to analyze the results obtained with revascularization and medical treatment in patients with symptomatic CNO, to compare periprocedural and follow-up results of CEA and CAS, and to identify factors related to technical failure, periprocedural complications, and restenosis.

MATERIALS AND METHODS

Study Design and Patient Selection

The CAOS study (in Spanish “CAsi Oclusión Sintomática”) is a nonrandomized, prospective, observational, multicenter registry study conducted in 17 Spanish university hospitals from January 2010 to May 2016. The CAOS study methodology has been described previously.²⁰ The study population comprised adult patients with an angiography-confirmed diagnosis of atherosclerotic CNO and ipsilateral ischemic stroke, TIA, or retinal ischemia in the previous 6 months. This study was supported by the “Stroke Project” initiative of the Spanish Cerebrovascular Diseases Study Group and obtained ethics approval from “Comité de Ética e investigación Clínica Hospital General Universitario Gregorio Marañón,” with ID number of the approval: 122/09. Participants gave informed consent before taking part in the study.

CNO was diagnosed in all patients using DSA. On the basis of the report by Fox et al,¹ diagnosis of ICA near-occlusion was confirmed when the angiographic findings fulfilled at least 2 of the following 4 criteria: 1) delayed cranial arrival of ICA contrast compared with the external carotid artery, 2) intracranial collaterals seen as cross-filling of contralateral vessels or ipsilateral contrast dilution, 3) frank reduced diameter of the ICA compared with the contralateral ICA, and 4) reduced ICA diameter compared with the ipsilateral external carotid artery. The presence or absence of a full collapse was determined by each participating center using DSA and/or CT angiography and defined as a “threadlike” lumen distal to the stenosis.²¹

The treatment decision (medical therapy versus revascularization) as well as the type of revascularization treatment (CEA or

CAS) was based on the criteria and routine practice of each participating center. Patients who underwent revascularization beyond 6 months were included in the medical treatment group, and their follow-up was censored at the time of the intervention.

Follow-up and Outcome Measures

The immediate result of the revascularization procedure was assessed in the CAS group by performing an angiographic control series after carotid stent implantation. In the surgical group, a non-invasive carotid imaging test (usually CT angiography or carotid sonography) was performed within 48 hours of the procedure. The result of the revascularization procedure was classified as follows: 1) complete revascularization if a complete or almost-complete recovery of the distal caliber of ICA was achieved, 2) incomplete revascularization when the distal ICA collapse persisted after the intervention, and 3) carotid occlusion when the procedure resulted in complete occlusion of the treated ICA. Revascularization failure was defined as incomplete revascularization or a complete occlusion occurring immediately after the procedure.

Carotid imaging follow-up of the near-occlusion using carotid sonography, CT angiography, and/or MR angiography was performed at 6, 12, and 24 months. Restenosis (defined as a stenosis of >50% of the treated ICA) and complete ICA occlusion rates at 24-month follow-up were collected. Any periprocedural (ie, within 30 days after the procedure) stroke or death rate and other complications were recorded. A clinical follow-up was performed at 3, 6, 12, and 24 months after the presenting event.

The 24-month ipsilateral ischemic stroke rate (including periprocedural events) and mortality were also assessed. Disabling stroke was defined as a stroke associated with a 3-month mRS score of 3–5.

Statistical Analysis

Statistical analyses were performed using the SPSS Statistics 23.0 software package for Windows (IBM). The results were expressed as proportions for categorical variables and as mean (SD) or medians and interquartile range (IQR) for continuous variables. Categorical variables were compared using the χ^2 test or 2-tailed Fisher exact test. Continuous variables were compared using a 2-sample *t* test or the Mann-Whitney test. Univariate and age- and revascularization procedure-adjusted multivariate logistic regression analyses were performed to determine factors related to revascularization failure, periprocedural stroke, or death and restenosis. The cumulative incidences were calculated using Kaplan-Meier curves. Differences among treatment groups were determined using the log-rank test. *P* values $\leq .05$ were considered statistically significant.

RESULTS

A total of 141 patients with angiography-confirmed CNO were recruited. Most patients were men (120; 85.1%), with a mean age of 68.71 (SD, 9.05) years.

Seventy patients underwent revascularization. In 3 of them, the procedure was performed beyond 6 months, and patients were assigned to the medical treatment group. Therefore, 74 patients were included in the medical treatment group, and 67, in the revascularization group (44 CAS and 23 CEA procedures). No

Table 1: Baseline characteristics of the patients

	CEA (n = 23)	CAS (n = 44)	Medical Treatment (n = 74)	P Value
Demographics				
Age (mean) (SD) (yr)	68.6 (7.9)	68.4 (10.9)	69.0 (8.3)	.946
Age younger than 65 yr (No.) (%)	7 (30.4)	13 (29.5)	22 (31.1)	.985
Age 65–74 yr (No.) (%)	9 (39.1)	16 (36.4)	30 (40.5)	.904
Age 75 yr or older (No.) (%)	7 (30.4)	15 (34.1)	21 (28.4)	.809
Male sex (No.) (%)	19 (82.6)	39 (88.6)	62 (83.8)	.723
Time to revascularization				
Days to revascularization, (median) (IQR)	22 (11–53)	21 (8–39.5)		.930
Revascularization within 15 days after the presenting event (No.) (%)	8 (34.8)	20 (45.5)		.400
Risk factors				
Hypertension (No.) (%)	15 (65.2)	35 (79.5)	51 (68.9)	.352
Diabetes mellitus (No.) (%)	10 (43.5)	12 (27.3)	29 (39.2)	.311
Dyslipidemia (No.) (%)	13 (56.5)	21 (47.7)	39 (52.7)	.770
Current smoker (No.) (%)	9 (39.1)	17 (38.6)	23 (31.1)	.629
Ischemic heart disease (No.) (%)	2 (8.7)	8 (18.2)	13 (17.6)	.556
Atrial fibrillation (No.) (%)	0	1 (2.3)	6 (8.1)	.180
Previous stroke/TIA (No.) (%) ^a	4 (17.4)	11 (25)	20 (27)	.646
Peripheral artery disease (No.) (%)	3 (13)	5 (11.4)	5 (6.8)	.554
Clinical presentation				
Ipsilateral ischemic stroke or retinal infarct (No.) (%)	17 (73.9)	31 (70.5)	47 (63.5)	.566
Ipsilateral transient symptoms (No.) (%)	6 (26.1)	13 (29.5)	27 (36.5)	.566
Ipsilateral recurrent events (No.) (%)	4 (17.4)	7 (15.9)	13 (17.6)	.972
Full collapse (No.) (%) ^b	5 (23.8)	10 (33.3)	26 (41.3)	.332

^a The history of stroke/TIA before the index event.

^b The presence or absence of full collapse could be determined in 114 patients.

significant differences were observed in the baseline characteristics among CEA, CAS, and medical treatment groups (Table 1).

The median time from the presenting event to the revascularization was 21 days (IQR, 11–43 days), 22 for CEA and 21 for CAS. Ultra-early treatment (ie, within 24 hours) was performed in 4 patients, and 28 patients (41.8%) were treated in the 15 days following the event. One patient had an ipsilateral retinal infarct while awaiting CEA.

Complete revascularization was achieved in 56 patients (83.6%). Revascularization failure was observed in 11 patients (16.4%), incomplete revascularization occurred in 8 patients, and carotid occlusion during the procedure, in 3. No significant differences in the proportion of complete revascularization or failure were observed between CAS and CEA (Table 2).

Six patients (8.9%) had a periprocedural stroke or TIA, all of them ipsilateral to the treated CNO. Three strokes or TIAs occurred in the CAS group (6.8%, 1 disabling stroke and 2 TIAs), and the other 3 cases, in the CEA group (13%, all of them nondisabling strokes). The rate of periprocedural stroke or death was 6% ($n = 4$) and tended to be higher for CEA (13% versus 2.3%, $P = .077$). Revascularization failure was not associated with an increased risk of periprocedural events: Only 1 patient treated with CAS had an ICA occlusion and ipsilateral disabling stroke. None of the patients died within the first 30 days following the procedure, though 1 patient treated with CAS who had a cerebral hyperperfusion syndrome (CHS) died 67 days after the procedure. Twelve other periprocedural complications were registered (Table 2). CHS was recorded in 2 cases (3%), with no differences between surgical and endovascular treatments.

Carotid imaging follow-up was performed in 60 patients. Restenosis or ICA occlusion was detected in 5 patients (8.3%). Restenosis occurred in 3 patients (5%), all of them treated with CAS. In 1 patient, restenosis was symptomatic, presenting as an ipsilateral TIA. Progression to complete ICA occlusion was observed in 2 patients (3.3%), one (4.8%) in the surgical group and another (2.3%) in the CAS group ($P = .636$). The patient who progressed to ICA occlusion after endovascular treatment had a disabling ipsilateral stroke (Table 2).

Revascularization failure occurred more frequently in patients with full collapse: 33.3% compared with 5.6% ($P = .009$). Additionally, restenosis or ICA occlusion was more frequent in patients with CNO with full collapse (21.4% versus 2.9%, $P = .032$). No significant relationship was observed between the presence of full collapse and the risk of periprocedural stroke or death (6.7% in CNO with full collapse and 8.3% in CNO without full collapse, $P = .840$) or with CHS (6.7% and 2.8%, $P = .514$). In the multivariate analysis, the presence of full collapse was the only factor independently related to an increased risk of revascularization failure (OR, 11.6; 95% CI, 1.6–84.6) and restenosis at follow-up (OR, 27.4; 95% CI, 1.3–567.7) (Table 3).

Fifteen patients had an ipsilateral ischemic stroke during the 24-month follow-up, resulting in a cumulative rate of 11.1% (95% CI, 5.8%–16.4%). Two ipsilateral strokes occurred in the CAS group (cumulative rate, 4.8%; 95% CI, 0%–11.3%), 4 in the surgical group (1 before CEA and 3 in the periprocedural period, cumulative rate, 17.4%; 95% CI, 1.9%–32.9%), and 9 in the medical treatment group (13.1%; 95% CI, 5.1%–21.1%; $P = .223$) (Figure). We recorded 6 disabling strokes: 2 in the endovascular

Table 2: Revascularization results, periprocedural complications, carotid imaging follow-up, and clinical follow-up

	CEA (n = 23)	CAS (n = 44)	Medical Treatment (n = 74)	P Value
Immediate results of the procedure				
Complete revascularization	20 (87)	36 (81.8)		.360
Revascularization failure	3 (13)	8 (18.2)		
Incomplete revascularization	2 (8.7)	6 (13.6)		
ICA occlusion	1 (4.3)	2 (4.5)		
Periprocedural complications				
Ipsilateral stroke or TIA	3 (13)	3 (6.8)		.397
Disabling stroke	0	1 (2.3)		
Nondisabling stroke	3 (13)	0		
TIA	0	2 (4.5)		
Death	0	0 ^a		
Periprocedural stroke or death	3 (13)	1 (2.3)		.077
Other complications	5 (21.7)	7 (15.9)		.555
Stent thrombosis	0	1 (2.3)		
Cerebral hyperperfusion syndrome	1 (4.3)	1 (2.3)		
Epileptic seizures	0	1 (2.3)		
Complications in the puncture area	0	2 (4.5)		
Hypoglossal nerve palsy/dysphonia	3 (13.6)	0		
Asystolia/bradycardia	0	2 (4.5)		
Airway compression	1 (4.3)	0		
Carotid-imaging follow-up				
Carotid restenosis or occlusion ^b	1 (4.5)	4 (10.5)		.419
Carotid restenosis	0	3 (6.8)		.200
Symptomatic carotid restenosis	0	1 ^c		
Carotid occlusion	1 (4.8)	1 (2.3)		.636
Symptomatic carotid occlusion	0	1 ^d		
Clinical follow-up				
Ipsilateral ischemic stroke at 24 months' follow-up	4 (17.4)	2 (4.8)	9 (13.1)	.223
Mortality at 24 months' follow-up	1 (4.5)	5 (12)	4 (5.6)	.422

^a One patient had cerebral hyperperfusion syndrome and died 67 days after the procedure.

^b Carotid imaging follow-up was performed in 62 patients (22 in the CEA group and 40 in the CAS group).

^c Carotid restenosis manifested clinically as a TIA.

^d Disabling ipsilateral stroke.

group (cumulative rate, 4.8%), none in the CEA group, and 4 in the medical treatment group (5.8%, $P = .518$).

Ten patients died during follow-up. The 24-month cumulative mortality rate was 7.5% (95% CI, 3.0%–12.0%). Five deaths occurred in the endovascular group (12%; 95% CI, 2.2%–21.8%), 1 patient died in the CEA group (4.5%; 95% CI, 0%–13.1%), and 4, in the group of patients treated medically (5.6%; 95% CI, 0.3%–10.9%) ($P = .422$; Figure).

DISCUSSION

In the present study, a revascularization rate of 84% was obtained with no significant differences between CEA and CAS. Our revascularization results are lower than those observed in previous series with success rates well above 90%.^{10,11,15–17} However, these results come from retrospective single-center studies in which selection biases cannot be ruled out.

Traditionally, CNO revascularization has been associated with a high risk of complications. However, the NASCET and ECST studies showed similar periprocedural stroke and death rates for CNO and conventional ICA stenosis (5.4% and 6.2%, respectively),² and a recent meta-analysis found a perioperative risk of 4.8% for CEA and 5.4% for CAS.⁸ The periprocedural stroke and death rate was 6% in our study and was especially high in the CEA group (13% versus 2.3%). These poor results should be viewed with caution considering the small number of patients


included in each treatment group, which could be overstating some of our results. Furthermore, all 3 perioperative strokes that occurred in the CEA group were nondisabling.

The incidence of CHS after carotid revascularization ranges between 0% and 3%.²² However, a recent meta-analysis described a higher incidence for patients treated with CAS, reaching 4.6%.²³ The incidence of CHS could also be higher in patients with CNO: Cay et al²⁴ reported an 8.6% rate after CAS and observed a significantly higher risk among patients with full collapse (30% compared with 4.2% in CNO without full collapse). A decreased cerebral autoregulation or underlying blood-brain barrier damage has been proposed to explain this finding. In our study, CHS occurred in 3% of cases, and no differences were observed between CAS and CEA or between CNO with or without full collapse.

Restenosis or ICA occlusion at 2-year follow-up was detected in 8.3% of our patients and occurred more frequently with CAS (10.5% versus 4.5%), though the difference did not reach statistical significance. Pooled analyses found a rate of restenosis in patients with CNO that ranged between 4% and 6.4% for CEA and 4.1% and 7.5% for CAS,^{8,9} not very different from the restenosis rate of 4%–5% at 1 year for conventional ICA stenosis described in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).¹⁸ However, Kim et al¹⁷ observed a higher proportion of restenosis in CNO, reaching 20% for CAS and 17.4% for CEA.

Table 3: Factors related to revascularization failure, periprocedural stroke or death, and carotid restenosis

	Revascularization Failure		Periprocedural Stroke or Death		Carotid Restenosis or Occlusion at Follow-up	
	Univariate Analysis	Multivariate Analysis ^a	Univariate Analysis	Multivariate Analysis ^a	Univariate Analysis	Multivariate Analysis ^a
Age 75 yr or older	1.91 (0.51–7.13)		2.15 (0.28–16.38)		3.66 (0.56–24.00)	
Male sex	0.64 (0.12–3.61)		0.44 (0.04–4.72)			
Hypertension	4.00 (0.47–33.86)		1.02 (0.10–10.53)			
Diabetes mellitus	0.40 (0.08–2.03)		2.15 (0.28–16.38)		0.51 (0.05–4.94)	
Dyslipidemia	0.30 (0.07–1.26)		0.97 (0.13–7.31)		1.56 (0.24–10.05)	
Current smoker	0.54 (0.13–2.25)		1.63 (0.22–12.31)		1.00 (0.15–6.48)	
Ischemic heart disease	2.63 (0.56–12.31)		2.00 (0.19–21.41)		1.71 (0.17–17.63)	
Previous stroke/TIA	1.375 (0.32–6.00)		1.17 (0.11–12.11)		0.90 (0.09–8.78)	
Clinical presentation as transient symptoms	0.37 (0.04–3.16)		1.42 (0.14–14.84)		3.41 (0.50–23.39)	
Full collapse	8.50 (1.43–50.66) ^b	11.60 (1.59–84.63) ^c	0.79 (0.08–8.22)		9.27 (0.87–98.51) ^d	27.40 (1.32–567.74) ^e
CEA vs CAS	0.68 (0.16–2.84)		6.45 (0.63–65.93)		0.41 (0.04–3.87)	

^a Age- and revascularization procedure-adjusted multivariate logistic regression analysis.^b $P = .019$.^c $P = .016$.^d $P = .065$.^e $P = .003$.**FIGURE.** Kaplan-Meier curves comparing the effect of CAS (green line), CEA (blue line), and medical treatment (black line) on the cumulative rate of ipsilateral ischemic stroke (A) and mortality (B).

Recent meta-analyses have described a long-term stroke rate below 5% in patients with CNO who undergo revascularization.^{8,9} The 24-month cumulative stroke rate is strikingly higher in our study, especially for CEA, reaching 17%. These results are clearly related to the high rate of periprocedural stroke observed in proportion to the small number of patients included in this treatment group. On the other hand, if we re-analyze the cumulative recurrence rate in the CEA group and consider the event that occurred before surgery as a recurrence in the medical treatment group, the cumulative rates of both groups would be similar

(13.6% for CEA and 14.3% for medical treatment). In any case, our study has not been able to show clear differences in the risk of recurrent stroke at 2 years among the different treatment groups.

Full collapse has been associated with an increased risk of recurrence in medically treated patients with CNO,^{5,6} though this effect has not been confirmed in all studies.²⁵

On the other hand, the impact of full collapse on the results of the revascularization of CNO has been less often studied. In our study, CNO with full collapse was associated with a greater

probability of revascularization failure (33% versus 6%). This finding may be explained by the technical difficulties involved in fully expanding the stent in a narrow artery or in implanting a shunt in patients treated with CEA. The study by Neves et al²⁶ also showed a high failure rate with CAS (21%) in patients with CNO and full collapse. Other studies do not seem to confirm these findings.^{24,27} We also observed an increased risk of restenosis or ICA occlusion in patients with collapsed CNO. Meershoek et al²⁷ did not record restenosis in their 17 patients with CNO with full collapse treated with CEA, and Neves et al described 2 occlusions during follow-up in their 19 patients treated with CAS. Recently, Johansson et al²⁸ have described a high rate of postprocedural stroke or death in patients with CNO and full collapse (2 of 10 versus 0 of 43 in CNO without full collapse and 5 of 166 in conventional carotid stenosis). Most interesting, the 2 cases described were intracerebral hemorrhages. In our study, no association was observed between the presence of full collapse and the risk of periprocedural stroke or death.

This study has some limitations. First, this is a subanalysis of a previous study, which was not specifically designed to compare CEA, CAS, and medical treatment. Second, the sample size of the study does not have sufficient statistical power for an adequate comparison between CEA and CAS; therefore, the periprocedural stroke rate in the CEA group could have been overestimated. On the other hand, the small number of patients with CNO and full collapse may have affected the precision of the multivariate analysis. Third, patients were not randomized to medical or revascularization treatment and CEA or CAS; treatment decisions were based on the criteria of each participating center. Fourth, the study provides limited information on the technical aspects of the different treatments used. The main strength of this study is its prospective design and the use of predefined diagnostic criteria for CNO.

CONCLUSIONS

Our results suggest that revascularization of CNO is a technically challenging procedure with a high failure rate and an increased risk of periprocedural stroke and other potentially serious complications such as CHS. In addition, revascularization in patients with CNO with full collapse appears to be associated with a higher risk of technical failure and restenosis. On the other hand, CAS or CEA was not associated with a significant reduction of ipsilateral stroke at follow-up compared with medical treatment.

These findings raise new questions about the optimal management of CNO and force us to consider the risk-benefit balance between medical treatment and revascularization in this group of patients.

Future research in CNO should focus on the following:

- A better understanding of the pathophysiology and natural history of CNO
- Elucidating the impact that the presence or absence of full collapse may have in patients with CNO
- Identifying other factors associated with an increased risk of stroke

- Studies specifically designed to allow comparison between medical treatment and revascularization and between CEA and CAS.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

1. Fox AJ, Eliasziw M, Rothwell PM, et al. **Identification, prognosis, and management of patients with carotid artery near occlusion.** *AJNR Am J Neuroradiol* 2005;26:2086–94 [CrossRef Medline](#)
2. Rothwell PM, Eliasziw M, Gutnikov S. A, et al. **Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.** *Lancet* 2003;361:107–16 [CrossRef Medline](#)
3. Rothwell PM, Gutnikov SA, Warlow CP; European Carotid Surgery Trialists' Collaboration. **Reanalysis of the final results of the European Carotid Surgery Trial.** *Stroke* 2003;34:514–23 [CrossRef Medline](#)
4. Naylor AR, Ricco JB, de Borst GJ, et al. **Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).** *Eur J Vasc Endovasc Surg* 2018;55:3–81 [CrossRef Medline](#)
5. Johansson E, Öhman K, Wester P. **Symptomatic carotid near-occlusion with full collapse might cause a very high risk of stroke.** *J Intern Med* 2015;277:615–23 [CrossRef Medline](#)
6. Gu T, Aviv RI, Fox AJ, et al. **Symptomatic carotid near-occlusion causes a high risk of recurrent ipsilateral ischemic stroke.** *J Neurol* 2020;267:522–30 [CrossRef Medline](#)
7. Antonopoulos CN, Giosdekos A, Mylonas SN, et al. **Management of internal carotid artery near-occlusion: the need for updated evidence.** *Ann Transl Med* 2020;8:1263–63 [CrossRef Medline](#)
8. Xue S, Tang X, Zhao G, et al. **A systematic review and updated meta-analysis for carotid near-occlusion.** *Ann Vasc Surg* 2020;66:636–45 [CrossRef Medline](#)
9. Meershoek AJ, Vries EE, Veen D, et al; NEON Study Group. **Meta-analysis of the outcomes of treatment of internal carotid artery near occlusion.** *Br J Surg* 2019;106:665–71 [CrossRef Medline](#)
10. González A, Gil-Peralta A, Mayol A, et al. **Internal carotid artery stenting in patients with near occlusion: 30-day and long-term outcome.** *AJNR Am J Neuroradiol* 2011;32:252–58 [CrossRef Medline](#)
11. Akkan K, Ilgit E, Onal B, et al. **Endovascular treatment for near occlusion of the internal carotid artery.** *Clin Neuroradiol* 2018;28:245–52 [CrossRef Medline](#)
12. Kniemeyer HW, Aulich A, Schlachetzki F, et al. **Pseudo- and segmental occlusion of the internal carotid artery: a new classification, surgical treatment and results.** *Eur J Vasc Endovasc Surg* 1996;12:310–20 [CrossRef Medline](#)
13. Radak DJ, Tanaskovic S, Ilijevski NS, et al. **Eversion carotid endarterectomy versus best medical treatment in symptomatic patients with near total internal carotid occlusion: a prospective non-randomized trial.** *Ann Vasc Surg* 2010;24:185–89 [CrossRef Medline](#)
14. Berman SS, Bernhard VM, Erly WK, et al. **Critical carotid artery stenosis: diagnosis, timing of surgery, and outcome.** *J Vasc Surg* 1994;20:499–508 [CrossRef Medline](#)
15. Ruiz-Salmerón RJ, Gamero MA, Carrascosa C, et al. **Carotid artery stenting: clinical and procedural implications for near-occlusion stenosis.** *Neurologia* 2013;28:535–42 [CrossRef Medline](#)
16. Yan D, Tang X, Shi Z, et al. **Perioperative and follow-up results of carotid artery stenting and carotid endarterectomy in patients with carotid near-occlusion.** *Ann Vasc Surg* 2019;59:21–27 [CrossRef Medline](#)
17. Kim J, Male S, Damania D, et al. **Comparison of carotid endarterectomy and stenting for symptomatic internal carotid artery near-occlusion.** *AJNR Am J Neuroradiol* 2019;40:1207–12 [CrossRef Medline](#)
18. Brott TG, Howard G, Roubin GS, et al; CREST Investigators. **Long-term results of stenting versus endarterectomy for carotid-artery stenosis.** *N Engl J Med* 2016;374:1021–31 [CrossRef Medline](#)

19. Bonati LH, Dobson J, Featherstone RL, et al. **Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial.** *Lancet* 2015;385:529–38 [CrossRef Medline](#)
20. García-Pastor A, Gil-Núñez A, Ramírez-Moreno JM, et al; Stroke Project of the Spanish Cerebrovascular Diseases Study Group. **The risk of recurrent stroke at 24 months in patients with symptomatic carotid near-occlusion: results from CAOS, a multicentre registry study.** *Eur J Neurol* 2019;26:1391–98 [CrossRef Medline](#)
21. Johansson E, Fox A. **Carotid near-occlusion: a comprehensive review, Part 1: definition, terminology, and diagnosis.** *AJNR Am J Neuroradiol* 2016;37:2–10 [CrossRef Medline](#)
22. van Mook WN, Rennenberg RJ, Schurink GW, et al. **Cerebral hyperperfusion syndrome.** *Lancet Neurol* 2005;4:877–88 [CrossRef Medline](#)
23. Huibers AE, Westerink J, de Vries EE, et al. **Editor's choice: cerebral hyperperfusion syndrome after carotid artery stenting—a systematic review and meta-analysis.** *Eur J Vasc Endovasc Surg* 2018;56:322–33 [CrossRef Medline](#)
24. Cay F, Cil BE, Balci S, et al. **Relevance of distal arterial collapse in stenting of atherosclerotic near-occlusion of the carotid artery.** *AJNR Am J Neuroradiol* 2020;41:1054–60 [CrossRef Medline](#)
25. García-Pastor A, Gil-Núñez A, Ramírez-Moreno JM, et al; Stroke Project of the Spanish Cerebrovascular Diseases Study Group. **Comment on the article “Symptomatic carotid near-occlusion causes a high risk of recurrent ipsilateral ischemic stroke” by Gu et al.** *J Neurol* 2020;267:849–51 [CrossRef Medline](#)
26. Neves CR, Casella IB, da Silva ES, et al. **Medical therapy for asymptomatic patients and stent placement for symptomatic patients presenting with carotid artery near-occlusion with full collapse.** *J Vasc Interv Radiol* 2018;29:998–1005 [CrossRef Medline](#)
27. Meershoek AJ, Vonken EP, Nederkoorn PJ, et al. **Carotid endarterectomy in patients with recurrent symptoms associated with an ipsilateral carotid artery near occlusion with full collapse.** *J Neurol* 2018;265:1900–05 [CrossRef Medline](#)
28. Johansson E, Gu T, Castillo S, et al. **Intracerebral haemorrhage after revascularisation of carotid near occlusion with full collapse.** *Eur J Vasc Endovasc* 2022;63:523–24 [CrossRef Medline](#)